哮喘女性分娩住院期间抗高血压药物与宫缩剂的使用
基于行政数据库2006至2015年5,691,178例分娩住院分析,哮喘患者使用卡前列素氨丁三醇(carboprost)的调整风险比为0.68(95%CI 0.62-0.74),使用拉贝洛尔的调整风险比为0.93(95%CI 0.90-0.97)。静脉拉贝洛尔与其他抗高血压药相比,哮喘持续状态风险显著增高(6.5 vs 1.7/1000次分娩住院,P<.01)。作者认为哮喘患者中减少β受体阻滞剂和卡前列素氨丁三醇的使用可能存在机会,并应谨慎使用这些药物。
要点
- 哮喘患者使用卡前列素氨丁三醇的调整风险比为0.68(95%CI 0.62-0.74)。
- 哮喘患者使用拉贝洛尔的调整风险比为0.93(95%CI 0.90-0.97)。
- 静脉拉贝洛尔与其他抗高血压药相比,哮喘持续状态风险显著增高(6.5 vs 1.7/1000次分娩住院,P<.01)。
核心结论
- 作者认为哮喘患者中减少β受体阻滞剂和卡前列素氨丁三醇的使用可能存在机会。
- 鉴于这些药物与哮喘持续状态的关联,作者认为在哮喘女性中应谨慎使用。
研究设计与样本
- 使用Perspective行政数据库,纳入2006至2015年因分娩住院且并发产后出血或子痫前期的女性。
- 分析哮喘诊断与特定宫缩剂和抗高血压药物使用的关系,采用调整风险比及95%CI作为效应量。
- 分析基于卡前列素氨丁三醇和静脉拉贝洛尔使用情况的哮喘持续状态风险。
主要发现
- 共分析5,691,178例女性,其中239,915例(4.2%)有子痫前期,139,841例(2.5%)有产后出血。
- 哮喘患者使用卡前列素氨丁三醇的比例为11.4%,无哮喘患者为18.0%。
- 哮喘患者使用静脉拉贝洛尔的比例为18.5%,无哮喘患者为16.7%。
- 未调整分析中,哮喘与卡前列素氨丁三醇使用可能性降低37%相关,与拉贝洛尔使用可能性增加11%相关。
- 调整分析中,哮喘与卡前列素氨丁三醇使用可能性降低32%相关(调整风险比0.68,95%CI 0.62-0.74),与拉贝洛尔使用可能性降低7%相关(调整风险比0.93,95%CI 0.90-0.97)。
临床怎么用
- 作者认为哮喘患者中减少β受体阻滞剂和卡前列素氨丁三醇的使用可能存在机会。
- 作者认为鉴于这些药物与哮喘持续状态的关联,在哮喘女性中应谨慎使用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate whether the diagnosis of asthma is associated with the use of specific uterotonic and antihypertensive medications during delivery hospitalizations. METHODS: We used Perspective, an administrative database, to determine whether women hospitalized for delivery complicated by postpartum hemorrhage or preeclampsia received uterotonics and antihypertensive medications differentially based on the absence or presence of asthma from 2006 to 2015. Given that carboprost and intravenous (IV) labetalol may be associated with asthma exacerbation, adjusted models for receipt of these medications were created with adjusted risk ratios with 95% CIs as measures of effect. Risk for status asthmaticus based on receipt of carboprost and IV labetalol was analyzed. RESULTS: Over the study period, a total of 5,691,178 women were analyzed, of whom 239,915 (4.2%) had preeclampsia and 139,841 postpartum hemorrhage (2.5%). Carboprost was used less frequently in patients with asthma compared with patients with no asthma (11.4% vs 18.0%) in comparison with IV labetalol, which was used more commonly when a diagnosis of asthma was present (18.5% vs 16.7%). In unadjusted analysis, the presence of asthma was associated with a 37% decrease in likelihood of carboprost use and an 11% increase in likelihood of labetalol use. In adjusted analysis, the presence of asthma was associated with a 32% decrease in likelihood of carboprost use (adjusted risk ratio 0.68, 95% CI 0.62-0.74) compared with a 7% decrease in labetalol use (adjusted risk ratio 0.93, 95% CI 0.90-0.97). Risk for status asthmaticus was significantly increased with use of IV labetalol compared with other antihypertensive medications (6.5 vs 1.7/1,000 delivery hospitalizations, P<.01). CONCLUSION: There may be an opportunity to reduce use of β-blockers and carboprost among patients with asthma. Given their association with status asthmaticus, these drugs should be used cautiously in women with asthma.
引用
- Booker WA, Siddiq Z, Huang Y, et al. Use of Antihypertensive Medications and Uterotonics During Delivery Hospitalizations in Women With Asthma. Obstet Gynecol. 2018. PMID: 29889742. doi:10.1097/AOG.0000000000002685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。